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The cystine-knot motif, made up of three intertwined disulﬁde bridges, is a
unique feature of several toxins, cyclotides and growth factors, and occurs
in a variety of species, including fungi, insects, molluscs and mammals.
Growth factor molecules containing the cystine-knot motif serve as ligands
for a diverse range of receptors and play an important role in extracellular
signalling. This superfamily of polypeptides comprises several homodimeric
and heterodimeric molecules that are central characters in both health and
disease. Amongst these molecules are a group of proteins that belong to
the vascular endothelial growth factor (VEGF) subfamily. The members of
this family are known angiogenic factors that regulate processes leading to
blood vessel formation in physiological and pathological conditions. The
focus of the present review is on the structural characteristics of proteins
that belong to the VEGF family and on signal-transduction pathways that
become initiated via the VEGF receptors.
Introduction
Disulﬁde bonds between pairs of cysteine residues in
some proteins form a unique functional signature and
are considered to be major determinants of protein sta-
bility and folding. The cystine-knot motif, formally
identiﬁed as a structural motif about 20 years ago [1],
is one such arrangement of disulﬁde bonds that is pres-
ent in peptides and proteins from a wide variety of
species. This knotted arrangement of disulﬁde bridges
is usually associated with b-sheet structures in proteins
in which they occur. Although the motif was initially
thought to be characteristic of some growth factors, it
soon became apparent that the cystine-knot is also
quite common in a variety of smaller peptides, espe-
cially the small cysteine-rich toxins. However, when
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tides were taken into account, the motif could not be
superimposed directly with those of the growth factors.
This led to the classiﬁcation of the cystine-knot-con-
taining proteins into three groups ([2]; Fig. 1): growth
factor cystine-knots (GFCKs), inhibitor cystine-knots
(ICKs) and cyclic cystine-knots (CCKs). The disulﬁde
connectivity in all these cystine-knot molecules is
identical. Usually six cysteine residues, labelled in
order from the N-terminus to the C-terminus, are
involved in forming the knot. The knot is an embedded
ring formed by two disulﬁde bridges and their connect-
ing backbone segments, which is penetrated by a third
disulﬁde bridge. The three disulﬁde bridges are formed
between Cys I and Cys IV, Cys II and Cys V and Cys
III and Cys VI (any intervening cysteine not involved
in the formation of a disulﬁde bond is conventionally
ignored from being labelled). The main distinguishing
feature between these three families is that the pene-
trating disulﬁde bridge for the GFCKs is Cys (I–IV)
while that for the other two families is Cys (III–VI).
The unique feature that distinguishes the CCKs from
the ICKs is the cyclic nature of their protein backbone.
One of the interesting features of cyclic peptides is that
knowledge of the peptide sequence does not reveal the
ancestral head and tail; knowledge of the gene
sequence is required for this. Post-translational linkage
of the N-terminal and C-terminal residues via a pep-
tide bond results in cyclisation of this molecule.
Growth factor cystine-knots
The cystine-knot superfamily of growth factors is a
diverse group of proteins that are involved in a range of
biological functions such as cell growth, organogenesis,
embryonic development, cell-to-cell communication and
differentiation, as well as tissue repair and remodelling.
In addition to being involved in many of the normal
physiological functions of the cell, these growth factors
are also known to inﬂuence the pathophysiological out-
come of several malignant disorders. GFCKs can be fur-
ther divided into four groups; each subfamily is
Fig. 1. Schematic representation of the three groups of cystine-knot
proteins [107]: GFCKs, ICKs and CCKs. The cysteine residues are
labelled I to VI and the disulﬁde bonds are shown as dotted lines.
Fig. 2. Ribbon representation of the four GFCK prototypes [108]. The cystine-knot motif is shown in all four structures as a ball-and-stick
model. The PDB codes for coordinates used are indicated in parentheses.
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factor-b (TGF-b), nerve growth factor (NGF), platelet-
derived growth factor (PDGF) and glycoprotein hor-
mones (GPHs) such as gonadotropins (Fig. 2). In addi-
tion to these well-known members, novel proteins are
being continuously added to the growing repertoire that
is the cystine-knot superfamily [3]. These new members
are collectively called the C-terminal cystine-knot
(CTCK) proteins. The proteins of this subfamily are
functionally diverse modular proteins that share a con-
served domain of about 90 amino-acid residues in their
C-terminal cysteine-rich region. Members of the CTCK
family include von Willebrand Factor, mucins, Cyr61
[cysteine-rich protein 61 (CCN)] proteins [4], Slit protein
and the Norrie Disease Protein. Phylogenetic analysis
[3] of the cystine-knot-containing proteins identiﬁed two
main branches: the TGF-b (1TFG) family forms one
deﬁnite group and the PDGF (1PDG), NGF (1BET)
and GPH (1HCN) families form the other main branch
of the phylogenetic tree.
Included in the PDGF family of cytokines is a sub-
group of growth factors that are encoded by several
genes which regulate the processes of angiogenesis and
lymphangiogenesis. This family of polypeptides is
known as the vascular endothelial growth factor
(VEGF) family of cystine-knots. This review focuses
on the structural homology shared by these growth
factors by virtue of the cystine-knot motif and how the
knot-like topology has played an important role in
receptor recognition and signalling transduction events
that lead to blood and lymphatic vessel development.
VEGF family: ligands
The VEGF family comprises six subgroups of proteins:
VEGF-A, -B, -C, -D and -E and placenta growth factor
(PlGF). These bioactive proteins exemplify the develop-
ment of distinct biological functionalities during the
process of blood vessel formation. These polypeptides
display a common structural architecture despite little
sequence homology (Fig. 3). The crystal structures of
these growth factors demonstrate that all have a similar
topology based on the cyclic-knot of cysteines involved
in both intrachain and interchain disulﬁde bonds. This
cysteine connectivity stabilizes the Ca framework of
these growth factors for elaboration of the solvent-
exposed loop regions that form the receptor-binding
surface on these polypeptides. The members of this fam-
Fig. 3. Sequence alignment of all human VEGF family proteins. The alignment was created using the program ALINE [109]. The amino acid
residues have been coloured based on similarity. Identical residues are shaded black and residues of similar character are coloured in shades
of grey. The cysteine residues that are involved in the formation of the knot are shaded yellow. They are numbered in order from N-terminus
to the C-terminus. The three disulﬁde bridges are formed between Cys I and Cys VI, Cys III and Cys VII, and Cys V and Cys VIII.
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mers and sometimes as heterodimers. These growth fac-
tors mediate their different biological roles by binding
to three high-afﬁnity tyrosine kinase receptors (Fig. 4):
vascular endothelial growth factor receptor (VEGFR)-
1, VEGFR-2 and VEGFR-3 [5–7]. VEGFR-1 and VEG-
FR-2 have differential kinase activation potentials,
although both are important for normal development.
VEGFR-1 and VEGFR-2 are primarily involved in
blood vessel growth, whereas VEGFR-3 is mainly
involved in haematopoiesis and lymphangiogenesis.
Apart from these three tyrosine kinases, different splice
forms of VEGF-A, VEGF-B and PlGF bind the sem-
aphorin receptors neuropilins (NRPs) 1 and 2 [8].
VEGF-E (the viral VEGF) has also been shown to bind
NRP-1, even though it lacks a heparin-binding domain.
Some of these isoforms also bind heparan sulfate proteo-
glycans (HSPGs). VEGFs and VEGFRs are also known
to form complexes with integrins and extracellular
matrix components.
Vascular endothelial growth factor-A
VEGF-A is the most potent and pivotal regulator of
angiogenesis and vasculogenesis. A highly speciﬁc
mitogen for vascular endothelial cells (ECs), VEGF-A
promotes extravasation of proteins from tumour-asso-
ciated blood vessels. Disruption of genes encoding
VEGF-A results in severe defects and abnormalities in
the development of the cardiovascular system. Hypoxia
is one of the major up-regulators of VEGF-A expression
and is thought to drive angiogenesis during organogene-
sis [9]. On the other hand, limited⁄reduced VEGF-A
supply to the tissues leads to inhibition of organ devel-
opment [10,11]. Alternative splicing of VEGF-A mRNA
produces ﬁve isoforms: VEGF-A121, VEGF-A145,
VEGF-A165, VEGF-A189 and VEGF-A206 (Fig. 5).
These isoforms differ in their heparin and heparan
sulfate-binding abilities.
VEGF is expressed in spatial and temporal associa-
tion with physiological as well as tumour angiogenesis
Fig. 4. A schematic representation of the various receptors characterized for the members of the VEGF family of cystine-knot proteins
[107]. VEGFR-1 (fetal murine sarcoma-like tyrosine kinase (Flt)-1), VEGFR-2 [kinase-insert domain receptor (KDR)] and VEGFR-3 (Flt-4) are
tyrosine kinase receptors. NRP-1 and NRP-2 (neuropilins) belong to the family of semaphorin receptors. HSPGs act as binding partners for
some of the isoforms of the VEGF proteins. The receptors have been coloured individually. The arrows point to the ligands that bind each of
these receptors and these have been coloured according to the receptor they represent.
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of vesiculo-vacuolar organelles that channel the blood-
borne proteins into the tumours. This forms an extra-
vascular ﬁbrin gel that stimulates ECs and tumour
cells to proliferate and migrate and also supports the
invasion of stromal cells into the growing tumours
[12]. The similar mechanism of VEGF-A induction
during physiological as well as tumour angiogenesis
explains why VEGF-A plays a central role in so many
types of diverse tumours.
VEGF-A expression can be stimulated by several
other factors, even in the presence of oxygen. Activated
oncogenes that are part of the ras⁄mitogen-activated
protein kinase (MAPK) signal transduction pathway
potentiate expression of VEGF-A mRNA [13]. Hypoxia-
independent production of VEGF-A can also be
brought about by hypoglycaemia [14] and by inactiva-
tion of tumour-suppressor genes such as von Hippel
Landau and p53 genes at both transcriptional and post-
transcriptional levels [15,16].
Fig. 5. Genomic (human, denoted with the preﬁx ‘h’) organization and alternative splice forms of VEGF-A, VEGF-B and PlGF [107]. The ex-
ons coding for the PDGF homology domain (orange), heparin-binding domain (dark blue) and NRP-binding domain (light blue) are indicated in
the ﬁgure. The exons are shown as oval, shaded structures, whereas the introns are represented by lines. The sizes and lengths of the ex-
ons and introns have not been drawn to scale.
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opment of many tumours. The production of anta-
gonistic VEGF-A mutants, VEGF receptor inhibitors,
antisense mRNA-expressing constructs, inhibitory sol-
uble receptors and humanized monoclonal antibodies
against human VEGF-A are some of the strategies
that are being undertaken to treat VEGF-induced
tumour angiogenesis. VEGF-A is also being used to
develop therapeutics for the treatment of diseases
related to dysfunctional angiogenesis [17,18].
Apart from its role as an endothelial-speciﬁc factor,
VEGF-A has also been classiﬁed as an angioneurin
because it is known to affect both vascular cell and
neural cell functions. Recent studies have shown that
VEGF-A has an important role to play in vessel and
neuronal wiring in the central nervous system (CNS).
VEGF-A, through its interaction with VEGFR-2,
induces vascularization of the neural tube via the for-
mation of a perineural vascular plexus [19]. It has
been shown that a spatial gradient formed by the dif-
ferent isoforms of VEGF-A is essential for proper
vessel patterning in the brain [20]. VEGF-A also reg-
ulates neuronal cell migration by interacting with
NRP-1 [21]. Besides its effects on synaptic plasticity
in the CNS and neuroprotective effects on different
neuronal cell types in both the CNS and the periph-
eral nervous system, it has also been shown that there
is strong evidence for an unsuspected link between
VEGF-A and motor neurons from the studies of
amyotrophic lateral sclerosis (ALS) [22,23]. Apart
from ALS, VEGF-A has been linked to several other
neurodegenerative diseases such as Alzheimer’s disease
[24] and Parkinson’s disease [25], and to neuropathies
such as those associated with diabetes, ischemia and
nerve injury.
Vascular endothelial growth factor-B
VEGF-B, like VEGF-A, occurs in alternately spliced
forms (Fig. 5): VEGF-B167 and VEGF-B186 [26,27].
VEGF-B is both structurally and functionally related
to VEGF-A and PlGF. The smaller isoform is highly
basic and is associated with the cell surface via
HSPGs. VEGF-B controls the bioavailability of VEGF-A
by forming heterodimers with it. Both isoforms of
VEGF-B are devoid of N-glycosylation sites, although
VEGF-B186 has an O-glycosylation site instead [26].
VEGF-B has wide tissue distribution, albeit overlap-
ping with VEGF-A, and experiments reveal that
VEGF-B can act as an EC growth factor [26]. VEGF-B
displays quite prominent expression in the developing
heart and in several muscle types during embryonic
development [28]. Gene-knockout studies performed in
mice by ablating VEGF-B expression revealed that
response to myocardial recovery from ischemia and
vascular occlusion is jeopardized [29]. Studies show
that VEGF-B167 (along with VEGF-A165 and PlGF-1)
can induce mast cell chemotaxis and has a role to
play in inﬂammatory and neoplastic angiogenesis [30].
VEGF-B has also been implicated in several pathologi-
cal conditions, such as metastases of cancer cells,
through activation of plasminogen activator, pulmo-
nary hypertension and growth of tumours [31]. Inter-
estingly, some recent studies implicate a role for
VEGF-B in lipid metabolism, a function not yet
assigned for an angiogenic growth factor [32].
Vascular endothelial growth factor-C
The VEGF homology domain in VEGF-C is ﬂanked
by unique N- and C-terminal extensions (Fig. 6). The
carboxy-terminal domain contains a repetitive pattern
of cysteine residues, Cys–X10–Cys–X–Cys–X–Cys. The
pro-peptide VEGF-C undergoes stepwise proteolytic
cleavage to form a 21-kDa protein [27,33]. Interest-
ingly, VEGF-C has been described to occur as a mix-
ture of covalently and noncovalently bound dimers
[34,35]. VEGF-C is expressed during embryonic devel-
opment in regions where lymph vessels sprout from
blood vessels. In adults, however, VEGF-C is mainly
restricted to the lymphatic endothelium and has been
implicated in the development of lymphatic vessels
[36,37]. C-terminally cleaved VEGF-C is a high-afﬁnity
ligand for VEGFR-3 and upon removal of both pro-
peptides it acquires binding afﬁnity for VEGFR-2. It
has a higher binding afﬁnity for VEGFR-3 than for
Fig. 6. Genomic (human) organization of
VEGF-C and VEGF-D precursor proteins
[107]. The PDGF homology domain (shown
in orange) in the precursor proteins is cova-
lently linked to the N-terminal and the
C-terminal pro-peptides via disulﬁde bonds
(S-S). The amino acid positions for each of
the three proteolytically processed domains
are shown in parentheses.
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members, VEGF-C does not bind heparin. It selec-
tively stimulates lymphangiogenesis in the chorioallan-
toic membrane, whereas VEGF-A promotes haematic
proliferation [33].
Vascular endothelial growth factor-D
VEGF-D is yet another member of the VEGF family
of proteins. It shares around 48% amino-acid sequence
identity with VEGF-C [38]. Like VEGF-C, the N-ter-
minal and C-terminal pro-peptides (Fig. 6) of VEGF-D
also undergo stepwise proteolytic cleavage to acquire
binding afﬁnity for VEGFR-2 and VEGFR-3 [39].
VEGF-D is a tumour angiogenesis factor and promotes
EC proliferation. Experiments with a mouse tumour
model reveal that VEGF-D stimulates lymphangiogene-
sis within tumours. It promotes tumour metastasis
via development of the lymph vessels by activating
VEGFR-3 and not VEGFR-2 [40]. VEGF-D is also
known to play a modiﬁer role by modulating the abun-
dance of lymphatic vessels in some tissues during
embryonic development [41,42]. In adults, VEGF-D is
localized in smooth muscle cells in a variety of tissues,
suggesting that it might play a role in facilitating rapid
repair of vessels in the event of tissue damage [43].
VEGF-D has also been implicated in mechanisms of
resistance to clinical anti-angiogenic agents. It has been
suggested that because VEGF-D is an alternative
ligand to VEGF-A for VEGFR-2, VEGF-D could be
potentially responsible for patients not responding, or
developing resistance, to Avastin [44].
Vascular endothelial growth factor-E
Pox viruses of the Orf family encode reading frames
for proteins called VEGF-E that show only 25-35%
amino-acid identity with VEGF-A (Fig. 3) but bind
with comparable afﬁnity to VEGFR-2 [45]. VEGF-E
isoforms display a considerable degree of sequence
variation [46]. They all lack a heparin-binding
domain, but some variants retain binding to NRP-1
[47]. The viral VEGFs are potent mitogens that stimu-
late proliferation of human ECs in vitro and vasculari-
zation of sheep skin in vivo with potencies equivalent
to that of VEGF-A [48]. It was also shown that
transgenic mice over-expressing the NZ7 variant of
VEGF-E showed increased vascularization in subcuta-
neous tissue without producing the oedematous lesions
typically present on the skin of VEGF-A transgenic
mice. Studies by Kiba et al. [49] showed that exchang-
ing the region encompassing loops L1 and L3 of the
VEGF-E variant NZ7 with the corresponding loops
from VEGFR-1-binding ligands, such as PlGF or
VEGF-A, strongly reduced the activity of this viral
VEGF, implying speciﬁc interactions between L1 and
L3, and VEGFR-2.
Vascular endothelial growth factor-F
VEGF-Fs are the snake-venom-derived VEGFs, vam-
min and VR-1. These VEGF homologues possess
< 50% amino-acid sequence identity (Fig. 3) with
VEGF-A165 [50]. The two VEGF-F proteins display
potent biological activities both in vitro and in vivo when
compared with VEGF-A165. VEGF-Fs are 25-kDa ho-
modimeric heparin-binding proteins with a markedly
short C-terminal region (of 16–17 residues). This
region does not bear any signiﬁcant homology to the
C-terminal region of other VEGF homologues. It was
shown that VEGF-F binds heparin-like molecules via
its C-terminal region and inhibits the biological activ-
ity of VEGF-A165 [51].
Placenta growth factor
The human term placenta codes for a VEGF homo-
logue known as the PlGF [52]. An alternative splicing
mechanism produces four isoforms of PlGF, numbered
1–4 (Fig. 5). PlGF mRNA is abundantly expressed in
placental tissue and is also present in very small
amounts in heart, lung, thyroid, goitre and skeletal
muscle. No expression of PlGF has been detected in
kidney and pancreas [53].
Hybridization studies have revealed that PlGF is
well conserved in the mammalian, bovine, chicken,
amphibian and insect genomes. This suggests that the
PlGF gene has speciﬁc and indispensable functions.
The importance of this protein is emphasized by the
fact that a dysfunctional⁄absent gene in a mouse
embryo leads to an impaired blood vessel network and
subsequently to the death of the embryo. The develop-
ment and cell-speciﬁc regulation of the process of
alternative mRNA splicing may have important conse-
quences for physiological and pathological processes.
Studies reveal a preferential expression of PlGF-2 in
the placental tissue and cell lines, suggesting that this
long form of PlGF may be involved in the growth and
maintenance of pregnancy [54].
PlGF is also induced in human keratinocytes during
wound healing [55], its expression regulated by key cyto-
kines released during an injury or a wound. It has also
been shown that melanoma progression in humans is
accompanied by deregulated, constitutive PlGF expres-
sion. PlGF, however, serves no apparent autocrine role
in melanoma proliferation. It has been established that
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aortic ECs and HUVECs [56], but not the ECs from
hepatic sinusoids [57]. PlGF isoforms have very little
mitogenic or permeability-enhancing activity. However,
they signiﬁcantly potentiate the action of low concentra-
tions of VEGF-A in vitro and more strikingly in vivo
[58]. Gene knockout studies by Carmeliet et al. [59]
revealed that synergistic cooperation between PlGF and
VEGF-A in pathological conditions is speciﬁc (Fig. 7).
Upregulation of PlGF by ECs leads to displacement of
VEGF-A from its receptor, thus increasing the bioavail-
ability of VEGF-A [60].
VEGF family: three-dimensional
structures and functional implications
The aim of angiogenesis research is to characterize
the ECs that originate from tumour tissues, to con-
tinue to identify biochemical targets and elucidate the
three-dimensional (3D) structures of all the macro-
molecules involved in the process of angiogenesis. It
is important to elucidate and quantify the structure–
function relationship of these macromolecules in para-
metric terms in order to correlate the dynamics of all
biological processes and unravel the complex path-
ways that are integrated into the process of blood
vessel formation. The 3D structures deﬁne the inter-
face of ligands and their receptors or other macromo-
lecular targets. Structural studies on the VEGF
family of proteins and their receptors have been the
focus of much research. The following section dis-
cusses the insights gained into the function of these
angiogenic factors by the study of their structures:
native as well as in complex with their cognate recep-
tors or antibodies generated speciﬁcally to abolish
ligand–receptor interactions.
Native structures: unbound forms
To date, crystal structures of the unbound forms of
the receptor-binding domains of VEGF-A [61], PlGF-1
[62] and VEGF-B [63] and VEGF-D [64], VEGF-E
[65] and VEGF-F [50] have been reported. All six
structures are remarkably similar to each other in their
topology, with distinct structural differences in the
N-terminal region (Fig. 8). A high degree of sequence
conservation of the structurally important residues
between these growth factors results in the same over-
all 3D structure being adopted. VEGF-D has an
extended N-terminal a-helix, which in the other three
structures is short with the preceding residues folding
away from the receptor-binding interface. The 3D
structures of these proteins is fashioned by a nonglob-
ular sheet-like structure made up of highly twisted
antiparallel b-strands with two distorted b-hairpin
loops on one side of the cystine-knot and a single loop
on the other. VEGF proteins occur as biological
homodimers in which the monomers associate via
hydrophobic interactions with the dimer axis perpen-
dicular to the plane of the b-sheet. Each monomer
consists of two a-helices and seven b-strands. There
are very few contacts between the two monomers at
the central, highly irregular and solvent-accessible
b-sheet region. This highly twisted (the largest twist is
observed in strand b4) and antiparallel b-sheet region
of the growth factors superposes well, even to the
extent of maintaining some of the important hydro-
gen-bonding donor and acceptor residues.
The dimeric structure is stabilized by the cystine-
knot motif and a hydrophobic core region (one per
monomer). The cystine-knot is formed by the ﬁrst two
bonds and the backbone of the intervening polypeptide
through which the third disulﬁde bridge passes. The
cystine-knot motif in the VEGF family of growth fac-
tors also consists of two interchain disulﬁde bonds that
hold the two monomers together. A conserved gap size
between the cysteines in the knot ensures that their
positions in the b-strands are maintained amongst all
VEGF proteins. All the cysteines involved in forming
the knot (including those involved in forming the inter-
chain disulﬁde bond) have their main-chain torsion
angles (/, w) within the range speciﬁed for a typical
b-strand. Conservation of a glycine residue at the posi-
tion that precedes the cysteine residue involved in the
formation of an interchain disulﬁde bond emphasizes
the importance of the motif in maintaining structural
integrity of the proteins belonging to this superfamily.
This glycine has been seen to maintain positive dihe-
dral main-chain conformation in all the structures
solved for the different VEGF proteins.
The cystine core provides excellent proteolytic resis-
tance and thermal stability to these growth factors.
Thermodynamic stability and thermal-stability analyses
of different disulﬁde mutants of VEGF-A, performed
by Muller et al. [66], showed that the cystine-knot is
responsible for entropic stabilization of the molecule
and that none of the disulﬁde bridges increases the
thermodynamic stability of VEGF-A. Crystal struc-
tures of the disulﬁde mutants revealed that the struc-
tural differences in these mutants were restricted to
differences in loop structures or differences in the
coplanar arrangement of the monomers in the dimer.
Although a similar thermodynamic characterization
has not been carried out for any of the other members
of the VEGF family, it is very likely that the other
members emulate similar thermodynamic properties.
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FEBS Journal 278 (2011) 4304–4322 ª 2011 The Authors Journal compilation ª 2011 FEBS 4311Fig. 7. Modiﬁcation of the EC response to VEGF-A (green) by PlGF (magenta) during pathological conditions [107]. When the concentration
of PlGF is low, both VEGFR-1 (purple) and VEGFR-2 (orange) bind VEGF-A and normal angiogenesis occurs (A). However, during pathological
conditions (B and C), there is an increase in the concentration of PlGF, which displaces VEGF-A from VEGFR-1 and thereby increases the
bioavailability of VEGF-A for VEGFR-2 [59].
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A considerable amount of structural information is
available for VEGF-A complexes. Three-dimensional
structures are available for VEGF-A in complex with
VEGFR-1 [67], Fab-12 [68], Fab-Y0317 [69], Fab-G6
and Fab-B20-4 [70]. The same is not true for the VEG-
FR-1-speciﬁc ligands VEGF-B and PlGF. Structural
data on VEGF-B (apart from the native form) include
the structure of this ligand in complex with a neutraliz-
ing antibody fragment, Fab2H10 [71] and in complex
with VEGFR-1 [72]. Only the complex of PlGF with
VEGFR-1 [73] has been reported to date. Recently,
the structure of VEGF-C was elucidated in complex
with VEGFR-2 [74] (Fig. 9).
The topology of the receptor–ligand complex is
essentially the same amongst the VEGF family of
ligands. Two receptor molecules ligate with the growth
factor, one at each of the two symmetrical ends of the
dimer formed by virtue of two intersubunit disulﬁde
bridges. This mode of antiparallel dimerization brings
into spatial proximity residues (from both monomers)
that are involved in binding receptors. Another strik-
ing feature of dimerization is the clustering of positive
amino acids (for some of the isoforms of the different
VEGF proteins). This region is believed to play an
important role in binding HSPGs and therefore
enhances their receptor-binding afﬁnity. Pairwise
superposition of these dimeric growth factors in their
receptor-bound state versus their native form results in
very low C
a displacement values, indicating that the
growth factors do not undergo any major conforma-
tional change and require no induced-ﬁt mechanism to
enable binding to their respective partners. However,
superposition of the C
a traces of these growth factors
reveals conformational differences at the N-terminal
region, some loop regions and the C-terminal region.
Interestingly, these loop regions form part of the
receptor-binding interface. These variable regions are
responsible for the functional differences observed
between the VEGF proteins. The compact and stable
framework provided by the cystine-knot confers upon
these growth factors the ability to recognize common
binding partners, whereas the variability of the loop
regions allows for the presentation of active residues
for speciﬁc binding interactions, which lead to a
diverse range of biological functions mediated by the
VEGF proteins. The description that follows focuses
mainly on the different VEGFR-1 complexes eluci-
dated so far, with some discussion on the similarities
and differences with the VEGFR-2 complex [74].
The interface between VEGFR-1 and its ligands is
ﬂat, largely hydrophobic and hence energetically
favoured by shape complementarity between the two
interacting surfaces. The two interfaces at each end of
the growth factor dimer are usually identical, with the
exception of loss⁄gain of a couple of residues from
both the receptor and the ligand. The structures of the
three VEGFR-1 complexes reveal that several nega-
tively charged residues seem to mediate receptor bind-
ing to some degree, although the contributions to
binding by these acidic residues (Asp63, Glu64 and
Glu67 from VEGF-A) seem to be essential for the
interaction of VEGF-A and PlGF with VEGFR-1
[75,76] but not so much for VEGF-B [77]. The major
VEGFR-1-binding determinants on VEGF-B are yet
to be established. Analysis of the amino-acid sequence
of VEGF-A, VEGF-B and PlGF shows that despite
low sequence homology within the residues interacting
with the receptor, the binding stretch is almost identi-
cal in all three complexes. Although only 33% of the
total residues contributed by the ligands to the binding
interface are conserved, the amino acids compensate
for the differences in the sequence between these three
members of the VEGF family by occupying structur-
ally equivalent positions and mediating very similar
Fig. 8. Ribbon representation of the members belonging to the VEGF family of growth factors [108]. VEGF-A is coloured green (2VPF; [61]),
VEGF-B is coloured orange-yellow (2C7W; [63]), VEGF-C is coloured bright orange (2X1W; [74]), VEGF-D is coloured pale green (2XV7; [64]),
VEGF-E is coloured pale cyan (2GNN; [65]), VEGF-F is coloured dark blue (2WQ8; [50]) and PlGF-1 is coloured magenta (1FZV; [62]).
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contribution of VEGFR-1 to the binding interface
remains unaltered because the residues presented to
the interface by the receptor are identical in all three
complexes. Most of these residues are involved in
interacting with their respective ligands via hydropho-
bic or hydrogen-bonding interactions. However,
important differences were observed when the surface
areas of these residues, accessible after ligand binding,
were analysed [72]. We hypothesize that these
differences in surface accessibility might play a seminal
role in deciding the importance of these residues in the
afﬁnity of these ligands towards VEGFR-1.
The structure of VEGF-C in complex with VEGFR-2
[74] revealed that the overall topology of the VEGFR-2
complex was essentially the same as the previously elu-
cidated VEGFR-1 complexes. VEGF-C has the same
topological fold and binds its receptor in a manner
similar to the other members of the VEGF family, and
the domain 2 of VEGFR-2 is structurally similar to
the domain 2 of VEGFR-1 with which it shares about
32% amino acid sequence identity. This architectural
similarity is, however, not carried through to the resi-
dues that interact with the growth factors in their
respective receptor complexes. The degree of dissimi-
larity was shown to increase when the electrostatic
potential of the binding interface in all the complexes
was taken into consideration [72]. The VEGFR-1 inter-
face, which is mainly basic, and the VEGFR-2 inter-
face, which is mainly negatively charged, supports the
speciﬁcity and receptor recognition proﬁle of the dif-
ferent members of the VEGF family.
Apart from these receptor complexes, several struc-
tures of antibody complexes have also been elucidated.
Most of these are structures of VEGF-A in complex
with different antibodies (Fig. 10). The structure of
Fig. 9. Ribbon representation of the different receptor–growth factor complexes [108]. The top panel shows the side view of the complex
while the bottom panel shows the front view. The receptor and the growth factor molecules have been labelled. VEGFR-1 is shown in light
blue, whereas VEGFR-2 is coloured dark blue. VEGF-A is coloured green, VEGF-B is coloured orange-yellow, VEGF-C is coloured bright
orange and PlGF-1 is coloured in magenta. The structures shown are VEGF-A8–109•VEGFR-1D2 complex (1FLT; [67]), VEGF-B10–108•VEGFR-
1D2 complex (2XAC; [72]), PlGF-1•VEGFR-1D2 complex (1RV6; [73]), and VEGF-C•VEGFR-2D2D3 complex (2X1W; [74]).
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fragment prepared from a murine monoclonal anti-
body has also been elucidated [71]. The most notable
difference between the two types of complexes lies in
the character of residues that mediate the interactions.
The structures show that receptor-bound complexes
favour nonpolar interactions, whereas uncharged polar
residues, such as tyrosine, threonine and serine, domi-
nate the antibody-bound complexes [71,72]. Despite
the differences in the sequence, comparative analysis of
the antibody complexes with the receptor complexes
revealed that the interacting segments from the respec-
tive dimeric growth factors bear a striking resem-
blance. The antibodies studied so far seem to span the
same expanse on the ligand surface and bring about
the neutralizing effect by steric hindrance, not by
inducing any conformational change to prevent the
receptor from binding to the growth factors.
Growth factors, signalling and
angiogenesis
Angiogenesis, the process of formation of new blood
vessels from pre-existing blood vessels, is a vital physio-
Fig. 10. Ribbon representation of the different antibody–growth factor complexes [108]. The top panel shows the side view of the complex
while the bottom panel shows the front view. The antibody and the growth factor molecules have been labelled. The different generations
of the VEGF-A-binding Fab molecules are shown in different shades of red, whereas Fab-binding VEGF-B is coloured marine blue. VEGF-A is
coloured green and VEGF-B is coloured orange-yellow. The structures shown are of the complexes of VEGF-A8–109 with Fab-12 (1BJ1; [68]),
Fab-Y0317 (1CZ8; [69]) and Fab-G6 (2FJG; [70]), and of VEGF-B with Fab-2H10 (2VWE; [71]).
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implicated in several diseased states and plays a funda-
mental role in the progression of tumours from their
dormant state to their malignant form. Angiogenic mol-
ecules, such as those that comprise the VEGF family of
cystine-knot growth factors, stimulate ECs to migrate,
proliferate and eventually differentiate into new blood
vessels through a complex process involving extensive
interplay between oncogenes and suppressor genes,
stimulatory and inhibitory molecules, proteases and
endogenous inhibitors and environmental factors such
as the oxygen level (hypoxia) or copper ion. Angiogene-
sis is such a complex phenomenon that a clear-cut dis-
tinction between angiogenic factors as being either
inducers or inhibitors would be an oversimpliﬁcation.
Some act as both direct and indirect inducers of the
process, while some function contextually, sometimes as
inducers and sometimes as inhibitors. It has been
experimentally established that the loss of control of
termination and stabilization of the blood vessels is
caused by the up-regulation of the positive regulators as
well as by the exhaustion of the endogenous inhibitors
of the process of blood vessel formation.
The ECs are central to the process of blood vessel
formation as they integrate a variety of signals arising
from growth factors, cell–matrix and cell–cell contacts.
It is now an accepted assumption that the critical event
in the regulation of the process of angiogenesis is the
signal transduction cascade involving members of the
VEGF family, especially VEGF-A. Several canonical
signalling pathways, such as the MAPK pathway and
the phosphatidylinositol 3-kinase (PI3K) pathway are
activated by these growth factors as a result of binding
to their high-afﬁnity tyrosine kinase receptors and
accessory co-receptors, and engagement of molecules
such as the integrins and other receptor systems. In
contrast to the well-deﬁned role of VEGFR-2 in angio-
genic signalling, the function of VEGFR-1 is not as
well understood and hence most of the biological
responses discussed below pertain to VEGFR-2-medi-
ated signalling (Fig. 11).
A fundamental cellular mechanism by which VEGF
maintains blood vessel stability and integrity is by acti-
vating anti-apoptotic signalling. VEGF inhibits cellular
apoptosis by activating Akt⁄protein kinase B via a
PI3K-dependent pathway [78,79]. VEGF also induces
the expression of anti-apoptotic proteins such as Bcl-2
and A1 [80]. These, in turn, inhibit activation of the
upstream caspases. Other signalling pathways that pro-
mote EC survival include crosstalk between integrins
and the VEGF receptors [81], the protein kinase C
(PKC) pathway [82] and the association of focal adhe-
sion kinase (FAK) with paxillin. An increase in the
degree of phosphorylation of FAK is a point of con-
vergence for diverse EC survival stimuli.
EC proliferation is mainly brought about by the
activation of the extracellular signal-regulated kinase
(ERK) 1⁄2 pathway [83,84]. Studies using PKC inhibi-
tors indicate that PKC isoforms (particularly a and f)
play a crucial role in VEGF mitogenic signalling.
PKC-dependent ERK activation is also known to
mediate cell proliferation induced by VEGF [85].
VEGF has been shown to induce ras-independent and
PKC-mediated induction of the Raf-MAPK⁄ERK
kinase (MEK)-ERK pathway (involving nitric oxide
(NO)-mediated Raf-1 activation) to stimulate cell
proliferation [86,87].
Cell migration is another key step in the process of
angiogenesis. VEGF induces the expression of prote-
ases that promote the degradation of the basement
membrane and therefore initiate cell migration. Several
experiments point to a critical role for FAK-associated
signalling in cell migration [88]. VEGF-induced chemo-
taxis is also brought about via the p38⁄MAPK path-
way. Activation of the p38 kinase by VEGF leads to
reorganization of the actin cytoskeleton, thereby stimu-
lating cell migration [89]. Studies have shown that NO
production, stimulated by VEGF, leads to podokinesis
of ECs and hence angiogenesis [90,91]. A direct role
for NO in VEGF-mediated cell migration came to
light when it was shown that Ser1177 of endothelial
nitric oxide synthase was phosphorylated via the
Akt-dependent pathway [92]. PLC (phospholipase C)-c
activation has also been implicated in mediating
cellular responses linked to cell migration stimulated
by VEGF [93].
The signalling mechanisms that underlie vascular
permeability are not very clearly understood. VEGF
induces the formation of fenestrae [94]. These are spe-
cialized regions of the plasma membrane that are
highly permeable to small solutes. This is a crucial pro-
cess by which VEGF regulates vascular permeability.
VEGFR-2 is the principal signalling pathway for
VEGF-mediated increase in vascular permeability
during the process of blood vessel formation.
Interestingly, unlike the pro-angiogenic VEGFs, the
anti-angiogenic VEGFs, such as VEGF165b, stimulate
vascular permeability by activating VEGFR-1 and not
VEGFR-2 [95]. Experiments reveal that VEGF-
induced vascular permeability initiates a series of
events, including mobilization of intracellular Ca
2+
[96], Src kinase activation [97] and stimulation of the
PI3K [98] and p42⁄p4MAPK pathways [99]. Ultra-
structural studies show that VEGF activation of ECs
in vitro leads to a very rapid loss of junctional integ-
rity, disassociation of the adherens junctions and actin-
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cellular gaps. These changes, which occur as a result of
VEGFR signalling, are thought to be regulated by
members of the Ras superfamily of small GTPases
(Rho⁄Rac⁄Cdc42). Rac in particular seems to be linked
to the formation of VEGF-induced fenestrae [100].
Stimulation of cellular responses by VEGFR-1
seems to be potentially dependent on the cell type.
Only a few functions have been attributed to activation
of VEGFR-1, all of which occur in non-ECs, including
stimulation of the migration of peripheral blood
monocytes by binding to PlGF [101], NO release in
trophoblasts [102], up-regulation of matrix metallopro-
teinases in vascular smooth-muscle cells [103]. Func-
tional expression of VEGFR-1 in adventitial
ﬁbroblasts is an important mediator in the pathogene-
sis of vascular remodelling after arterial injury [104]. It
was also shown that VEGFR-1 down-modulates VEG-
FR-2-mediated EC proliferation via the PI3K-dependent
pathways [105]. VEGFR-1-mediated ligand-induced
(PlGF-1 or VEGF-A) signal transduction in primary
monocytes was also shown to involve two MAPK
pathways: p38 and ERK1⁄2. The activation of these
two pathways is strongly dependent on the activation
of PI3K [106]. These studies identiﬁed the underlying
molecular basis for VEGFR-1-mediated signalling in
primary monocytes and helped to put VEGFR-1 on
the angiogenic signalling map as a functional receptor
in its own merit.
Conclusions and perspectives
The VEGF–VEGFR signalling pathway is considered
central to the process of angiogenesis, both in normal
growth and development as well as in pathological set-
tings. However, it is clear that the formation of stable
and functional blood vessels requires the concerted
action of multiple signalling cascades. In this light,
new pathways are emerging, both upstream as well as
downstream of the VEGF⁄VEGFR pathway, which
are being recognized as essential for normal angiogene-
sis. Despite the large amount of basic and clinical
Fig. 11. Schematic representation of the molecular players involved in angiogenesis signalling mediated by the interaction of VEGF-A with
VEGFR-2 [107]. The text includes all the references that were used to make the ﬁgure. DAG, diacyly glycerol; eNOS, endothelial nitric oxide
synthase; Grb2, growth factor receptor-bound protein 2; MEK, MAPK⁄ERK pathway; PKB, protein kinase B; Raf, rapidly accelerated ﬁbrosar-
coma; Ras, RAt sarcoma; Sos, son of sevenless.
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are only just beginning to unravel the different func-
tional roles played by the members of VEGF family
by virtue of their interactions with the VEGF recep-
tors. There still exist large gaps in our comprehension
of the exact mechanism of molecular control of vessel
growth and stability by the VEGF⁄VEGFR system.
We need a better understanding of the temporal and
spatial orchestration of the different angiogenic signal-
ling pathways to gain a deeper insight into the mecha-
nisms that govern activation of these cystine-knot
proteins, speciﬁcity of receptor–ligand interactions, co-
receptor choice and how these various inputs are inte-
grated at the cellular level to provide the biological
response needed. Answers to all these questions will
feed towards the design of better drugs⁄inhibitors tar-
geting VEGFs and the VEGFRs for use in anti-angio-
genic therapy. There is still so much to learn about
these molecules that angiogenesis research will only
intensify further in the years to come.
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